SCHEMBL5535536

SCHEMBL5535536

N#Cc1ccc2c3c(cccc13)C(=O)N(c1cccc(C(=O)O)c1)C2=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.69
MEN1 O00255 7/20 0.69
KDM4E B2RXH2 6/20 0.69
ALDH1A1 P00352 6/20 0.69
POLB P06746 4/20 0.53
L3MBTL1 Q9Y468 4/20 0.53
RECQL P46063 3/20 0.53
CASP6 P55212 3/20 0.53
TDP1 Q9NUW8 3/20 0.53
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
RXFP1 Q9HBX9 3/20 0.53
APEX1 P27695 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
TYMS P04818 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.49
MAPK1 P28482 1/20 0.47
S100B P04271 1/20 0.47
USP2 O75604 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3285543 0.85 KMT2A (0.62) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL14172750 0.82 KMT2A (0.72) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL5168401 0.81 KMT2A (0.73) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL5150543 0.80 KMT2A (0.70) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL16602052 0.79 KMT2A (0.70) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL1514286 0.78 L3MBTL1 (0.73) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL5528602 0.78 KMT2A (0.56) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL4235162 0.78 MEN1 (0.70) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL29549557 0.77 TYMS (0.71) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL7825377 0.77 TYMS (0.71) KMT2AMEN1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KMT2A 4267/4885MEN1 3865/4885KDM4E 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.